Brief Communication
Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
M. Pereira Barbosaa, A. Bugalho de Almeidab, C. Pereirac,
, C.-W. Chend, P. Georgioue, G. Peacheye, on behalf of eXpeRience study group
Corresponding author
a Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
b Clínica Universitária de Pneumologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
c Novartis Farma – Produtos Farmaceuticos S.A., Avenida Professor Doutor Cavaco Silva, n.° 10E, Taguspark, 2740-255 Porto Salvo, Portugal
d Novartis Pharmaceuticals Corporation, One Health Plaza East Hanover, NJ 07936-1080, USA
e Novartis Pharmaceuticals UK Limited, Wimblehurst Road Horsham, West Sussex RH12 5AB, UK
Read
640
Timeswas read the article
326
Total PDF
314
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 4 | 7 | 11 |
| 2024 April | 28 | 24 | 52 |
| 2024 March | 34 | 23 | 57 |
| 2024 February | 27 | 30 | 57 |
| 2024 January | 18 | 18 | 36 |
| 2023 December | 17 | 28 | 45 |
| 2023 November | 21 | 25 | 46 |
| 2023 October | 17 | 44 | 61 |
| 2023 September | 20 | 28 | 48 |
| 2023 August | 18 | 19 | 37 |
| 2023 July | 22 | 26 | 48 |
| 2023 June | 15 | 13 | 28 |
| 2023 May | 43 | 29 | 72 |
| 2023 April | 30 | 12 | 42 |
Show all
